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Abstract X-ray repair cross-complementing group 1
(XRCC1) gene Arg194Trp polymorphism has been reported
to be associated with risk of lung cancer in many published
studies. Nevertheless, the research results were inconclusive
and conflicting. To reach conclusive results, several meta-
analysis studies were conducted by combining results from
literature reports through pooling analysis. However, these
previous meta-analysis studies were still not consistent.
Hence, we used an updated and cumulative meta-analysis to
get a more comprehensive and precise result from 25 case–
control studies searching through the PubMed database up to
September 1, 2013. The meta-analysis was carried out by the
Comprehensive Meta-Analysis software and the odds ratio
(OR) with 95 % confidence interval (CI) was used to estimate
the pooled effect. The result involving 8,876 lung cancer
patients and 11,210 controls revealed that XRCC1 Arg194Trp
polymorphism was not associated with lung cancer risk
[(OR=0.97, 95 %CI=0.92–1.03) for Trp vs. Arg; (OR=
0.92, 95 % CI=0.85–0.98) for ArgTrp vs. ArgArg; (OR=
1.07, 95 % CI=0.92–1.23) for TrpTrp vs. ArgArg; (OR=
0.93, 95 % CI=0.87–1.00) for (TrpTrp+ArgTrp) vs. ArgArg;
and (OR=1.08, 95%CI=0.94–1.25) for TrpTrp vs. (ArgTrp+
ArgArg)]. The cumulative meta-analysis showed that the re-
sults maintained the same, while the ORs with 95 % CI were
more stable with the accumulation of case–control studies.
The sensitivity and subgroups analyses showed that the results
were robust and not affected by any single study with no
publication bias. Relevant studies might not be needed for
supporting these results.
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Introduction
X-ray repair cross-complementing group 1 (XRCC1) is in-
volved in base excision repair protein that located on chromo-
some 19q13.2–13.3 with a length of 33 kb [1–4]. The poly-
morphisms of XRCC1 gene have been identified as three
categories of codons 194(Arg to Trp), 280(Arg to His), and
399 (Arg toGln) [5, 6]. One of them, Arg194Trp polymor-
phism was first reported in 1998 by Shen and coworkers [7].
In 2001, David-Beabesand coworkers [8] found that
Arg194Trp polymorphism might contribute to lung cancer in
African-American and Caucasian. Ratnasinghe and coworker
[5] found similar results in Chinese during the same year.
Later on, many molecular epidemiological studies reported
the association of XRCC1 Arg194Trp with lung cancer sus-
ceptibility [5, 8–30]. However, these results remain conflict-
ing and inconclusive. To reach conclusive results, several
meta-analysis studies were conducted by combining results
across studies from literatures through pooling analysis. How-
ever, these previous meta-analysis investigations were still not
consistent [31–33]. Furthermore, new published research
studies were coming out, but the inconclusive results are still
a problem to be resolved. Therefore, the association of
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Arg194Trp with lung cancer susceptibility with lung cancer
risk remains unclear.
In order to obtain more comprehensive and precise results,
we conducted cumulative meta-analysis [34, 35] to explore the
truly association between Arg194Trp polymorphism and lung
cancer risk based on 25 case–control studies. The meta-analysis
is reported based on preferred reporting items for systematic
reviews and meta-analyses (PRISMA) [36] statement.
Material and methods
Inclusion criteria
A study met all of the following inclusion criteria was included:
(1) to evaluate the association between XRCC1 Arg194Trp
polymorphism and risk of lung cancer; (2) cohort or case–control
design and the patientswere diagnosed by histology or pathology;
Fig. 1 Flow chart from identification of eligible studies to final inclusion
Table 1 Characteristics of included studies
References Country (ethnicity) Case Source of
control
Control Genotyping HWE
N ArgArg ArgTrp TrpTrp N ArgArg ArgTrp TrpTrp
David-Beabes [8] USA (Caucasian) 180 158 22 0 PB 461 407 54 0 PCR-RFLP 0.39
David-Beabes [8] USA (African-Americans) 154 142 10 2 PB 243 205 36 2 PCR-RFLP 0.67
Ratnasinghe [5] China (Asian) 108 52 47 9 PB 216 85 104 21 TaqMan 0.22
Chen [9] China (Asian) 109 48 44 11 PB 109 57 40 5 PCR-RFLP 0.79
Chan [10] China (Asian) 75 50 22 3 HB 162 79 67 16 PCR-RFLP 0.71
Hu [11] China (Asian) 710 335 311 64 HB 710 339 308 63 PCR 0.59
Hung [12] European (Caucasian) 2,188 1,878 259 10 HB 2,198 1,828 292 12 PCR 0.87
Schneider [13] Germany (Caucasian) 446 389 53 4 HB 622 544 75 3 PCR 0.74
Shen [14] China (Asian) 118 65 41 12 HB 112 64 40 8 PCR 0.62
Hao [15] China (Asian) 1,024 524 409 91 PB 1,118 572 459 87 PCR 0.77
Landi [16] Europe (Caucasian) 295 118 143 34 HB 314 123 149 42 PCR 0.96
Matullo [17] Europe (Caucasian) 116 98 16 2 PB 1,094 951 141 2 TaqMan 0.22
Zienolddiny [18] Norway (Caucasian) 336 309 26 1 PB 405 368 35 2 TaqMan 0.23
De Ruyck [19] Belgium (Caucasian) 110 101 8 1 HB 110 93 17 0 PCR-RFLP 0.38
Pachouri [20] India (Asian) 103 40 39 24 PB 122 52 47 23 PCR-RFLP 0.051
Yin [21] China (Asian) 241 120 98 23 HB 249 119 109 21 PCR-RFLP 0.65
Li [23] China (Asian) 350 184 136 30 HB 350 196 133 21 PCR-RFLP 0.89
Improta [22] Italy (Caucasian) 94 42 41 11 HB 121 53 61 7 PCR-RFLP 0.15
Chang [24] USA (Latinos) 113 89 23 1 PB 299 223 66 10 Illumina 0.1
Chang [24] USA (African–Americans) 255 221 34 0 PB 280 248 31 1 Illumina 0.97
Tanaka [25] Japan (Asian) 50 28 15 7 PB 50 25 23 2 PCR 0.47
Janik [26] Poland (Caucasian) 88 64 24 0 HB 79 51 28 0 PCR-SSCP 0.55
Buch [27] USA (Caucasian) 720 682 36 2 HB 928 839 83 6 Illumina 0.03
Wang [28] China (Asian) 209 105 83 21 HB 256 137 96 23 PCR-RFLP 0.59
Guo [29] China (Asian) 684 314 302 68 HB 602 265 274 63 PCR-LDR 0.58
N total sample size, PB population-based controls, HB hospital-based controls, HWE Hardy–Weinberg equilibrium, PCR-RFLP polymerase chain
reaction-restriction fragment length polymorphism, PCR-LDR polymerase chain reaction-ligase detection reaction, PCR-SSCP polymerase chain
reaction-single strand conformation polymorphism
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(3) the number of genotype distribution in both case and control
group were directly reported or calculated from the reported data;
and (4) the published language was English or Chinese.
Search strategy
The search terms [(“XRCC1” or “X-ray repair cross-
complementing group 1”) and “polymorphism” and (“lung
cancer” or “lung carcinoma”)] were used to search the
PubMed database up to September 1, 2013. The reference list
of the included articles and relevant meta-analyses were man-
ually searched.
Data extraction
Two authors independently chose 25 case–control studies,
which were illustrated in Fig. 1. The data were independently
extracted by authors according to the pre-specified table. The
following data were extracted: the surname of first author,
publication year, country origin and ethnicity, study design,
cancer type, source of control, number and genotyping distri-
bution of cases and controls, genotyping method, Hardy–
Weinberg equilibrium (HWE) for controls. Disagreements
were resolved through discussion with the third author.
Statistical analysis
Five genetic models [Trp vs. Arg; ArgTrp vs. ArgArg; TrpTrp
vs. ArgArg; (TrpTrp + ArgTrp) vs. ArgArg; and TrpTrp vs.
(ArgTrp + ArgArg)] were used to calculate the pooled odds ratio
(OR) and its 95% confidence interval (CI) to present the strength
of associations between XRCC1 Arg194Trp polymorphism and
risk of lung cancer. The fixed-effects model was used firstly, if
heterogeneity among included studies was detected by I2 statis-
tics (I2≤40 %) [37], we shifted to random-effects model. Sub-
groups analysis were conducted based on the ethnicity, source of
controls, cancer types, study design, and HWE for controls.
The influence of sample size on the overall risk estimation
was carried out by cumulative meta-analysis [35], and the
influence of single study on the overall risk estimation was
determined through sensitivity analysis by omitting one study
each time. The publication bias was detected by funnel plot
analysis. All the analysis was performed using the Compre-
hensive Meta-Analysis software, version 2.2 (Biostat, Engle-
wood, New Jersey) [38].
Results
Study section and characteristics
The electronic searching yielded 128 studies, and the hand
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involving 25 case–control studies [5, 8–29] contained 8,876
lung cancer patients and 11,210 controls were included.
Figure 1 presents flow chart of study selection. The main
characteristics of these eight studies were shown in Table 1.
Fig. 2 Forest plot based on Trp vs. Arg genetic model
Fig. 3 Forest plot for cumulative meta-analysis based on Trp vs. Arg genetic model
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Of them, three were multicenter studies [12, 16, 17], two
articles were included two case–control studies [8, 24], and
only one study was out of HWE [27].
Meta-analysis
Table 2 presented the overall and subgroups results of XRCC1
Arg194Trp polymorphism and lung cancer risk. Overall, the
heterogeneity of all five genetic models were acceptable
(I2≤40 %), and meta-analysis based on fixed-effects
model showed that there was no association of XRCC1
Arg194Trp polymorphism with risk of lung cancer
[(OR=0.97, 95 % CI=0.92–1.03) for Trp vs. Arg, Fig. 2;
(OR=0.92, 95 % CI=0.85–0.98) for ArgTrp vs. ArgArg;
(OR=1.07, 95 % CI=0.92–1.23) for TrpTrp vs. ArgArg;
(OR=0.93, 95 % CI=0.87–1.00) for (TrpTrp + ArgTrp) vs.
Fig. 4 Forest plot for sensitivity analysis based on Trp vs. Arg genetic model
Fig. 5 Funnel plot based on Trp
vs. Arg genetic model
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ArgArg; and (OR=1.08, 95 % CI=0.94–1.25) for TrpTrp vs.
(ArgTrp + ArgArg)].
The cumulative meta-analysis accumulated the studies ac-
cording to the publication year and showed that there was no
significant association between XRCC1 Arg194Trp polymor-
phism and lung cancer risk (Fig. 3). The sensitivity analysis
showed that the results were robust and were not influenced
by any single study (Fig. 4), with ORs in the range of 0.96–
0.98 and 95 % CIs in the range of 0.90–1.05. Subgroup
analysis upon source of control, ethnicity, and HWE also
revealed similar results (Table 2).
Publication bias
Figure 5 shows the funnel plot of based on Trp vs. Arg genetic
model. The relatively symmetric distribution indicated that
there was no publication bias, which was confirmed by
Egger’s test [(p=0.33 for Trp vs. Arg; p=0.12 for ArgTrp
vs. ArgArg; p=0.65 for TrpTrp vs. ArgArg; p=0.25 for
(TrpTrp + ArgTrp) vs. ArgArg; and p=0.50 for TrpTrp vs.
(ArgTrp + ArgArg))].
Discussion
Meta-analysis is a statistical method of combining results
across studies from literatures to resolve discrepancy in ge-
netic association studies [39]. The meta-analysis of 25 case–
control studies indicated that XRCC1 Arg194Trp polymor-
phism is not associated with lung cancer risk within human
populations, and subgroup analysis upon source of controls,
ethnicity, and HWE for controls is consistent with this result,
which was also supported by cumulative meta-analysis and
sensitivity analysis.
Compared to previously meta-analyses [31–33], the in-
cluded studies of our analysis are most precise and compre-
hensive attributing to the largest sample size and accumulative
meta-analysis method. Hence, the results are more precise and
comprehensive. In addition, cumulative meta-analysis was
performed to investigate the tendency of results by accumu-
lating single study year by year. This analysis could be used to
determine whether new relevant studies are needed or not.
Indeed, we found that the results remained the same when
studies were accumulated. Coincidentally, the sensitivity anal-
ysis indicated that the results were not influenced by any
single study. Hence, our results were more precise and useful
for appropriate care in lung cancer.
Obviously, there were potential to moderate level hetero-
geneity. From the subgroups analysis, we found that ethnicity
and source of control might not be the source of heterogeneity
(Table 2). When we deleted the study reported by Buch
et al.[27], which was not according to HWE any more, the
heterogeneity of all genetic models were decreased and the
results of all five genetic models were of no significance
(Table 2). This further indicated that violations and deviations
in HWE might be one source of heterogeneity and do largely
influence the results [40].
There were some limitations of our meta-analysis. First,
there was heterogeneity among included studies. Although the
heterogeneity was probably from the study reported by Buch
et al. [27], we could not conclude whether the heterogeneity
came from ethnicity or inconsistent results. Obviously, the
homogeneity of Asians and Caucasian was good, but only
the one combined with mixed ethnicities was significant.
Second, although no obvious publication bias was detected;
the funnel plot was not very symmetry. Our meta-analysis is
limited to language and database restrictions. The PubMed
database is the only search source and included published
studies were either in English or Chinese [28]. Third, this
meta-analysis was based on unadjusted data, lacking of de-
tailed genotype information stratified by main confounding
variables from original studies. Therefore, gene-gene and
gene-environment interactions remain unclear.
In conclusion, this meta-analysis suggests that XRCC1
Arg194Trp polymorphism is not associated with lung cancer
risk, either in Asians or Caucasians, either the controls were
sourced with or without HWE. These results were not influ-
enced by any single study, and relevant studies are not needed
for supporting this result. Due to the limitations of this meta-
analysis, current results should be viewed with caution and
future studies should be conducted in gene-gene and gene-
environment interactions.
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